Related Experiment Video
Updated: Jul 29, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer
Asmerom T Sengal1, Pamela M Pollock2
1Endometrial Cancer Laboratory, School of Biomedical Sciences, Faculty of Health, The Queensland University of Technology Located at the Translational Research Institute (TRI), Woolloongabba, Brisbane, QLD, Australia.
Abstract:
Patient-Derived Xenografts (PDXs) are established by implanting a fragment of a patient tumor into rodents either subcutaneously or orthotopically. PDX models faithfully recapitulate the histologic and molecular profile of the donor patient's cancer and are regarded as authentic preclinical models for drug testing, understanding of tumor biology and biomarker discovery. This Chapter describes the detailed method for establishing robust PDXs for endometrial cancer and provide important notes for users of the protocol to consider during PDXs development.
